ArticleCell2020
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.
3 registry-linked trialsOpen access · bronzeAbstract readClinical Trial, Phase I
In one paragraph
Article in Cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 473 papers.
0numbers the graph read from it
0cells of the map it votes in
473citing papers in PubMed
32.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety, Tolerability and Immunogenicity of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and Radiofrequency Ablation in Patients With Advanced Solid Tumors
Dendritic Cell Vaccination for the Adult Ovarian Cancer
NCT07686744 phase1not yet recruitingnot on this mapstarted 2026, after this paper: background citation
A Phase I Clinical Trial of Personalized Neoantigen Peptide Vaccine in Combination With Pembrolizumab for the Safety and Efficacy in Patients With Advanced, Recurrent or Refractory Renal Cell Carcinoma
Who cites it
473 citing papers in PubMed, 717 citations in OpenAlex.
- UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity.Cell reports. Medicine · 2025Trial
- TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation study.Nature communications · 2025Trial
- A data-driven cartography of NSCLC vaccine research: Quantifying the paradigm shift toward immuno-oncology combination therapies.Human vaccines & immunotherapeutics · 2026Review
- T cell immunomonitoring: a comparative analysis of traditional and novel methods to quantify and characterize human antigen-specific T cells.Nature protocols · 2026Review
- Self-Assembling Peptide-Adjuvant Conjugate (SaPAC) Platform for Precision Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Intramuscular plasmid DNA electroporation sequesters neoantigen-specific CD8Molecular therapy. Oncology · 2026Article
- Review
- Therapeutic cancer vaccines: development, challenges, and future perspectives.Acta pharmacologica Sinica · 2026Review
- Developing neoantigen cancer vaccines: where are we now?Nature communications · 2026Review
- Current landscape and future directions of neoantigen vaccines: A new era of personalized cancer immunotherapy.Innovation (Cambridge (Mass.)) · 2026Review
- Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer.Science advances · 2026Article
- Therapeutic vaccines for NSCLC: From mechanisms to clinical translation.Chinese medical journal pulmonary and critical care medicine · 2026Review
- Long-read sequencing reveals widespread novel splicing and neojunction-derived neoantigens in nasopharyngeal carcinoma.Genome research · 2026Article
- Artificial intelligence for translational personalized neoantigen cancer vaccine development.Journal of biomedical science · 2026Review
- Proximal Proteomics Reveals Potential Regulators of Programmed Death-Ligand 1 in Human Cancer.ACS omega · 2026Article
- Transcriptomic profiling and structural characterization reveal UQCRC1 and COX4I1 as key mitochondrial regulators associated with oxidative stress in multiple sclerosis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Cancer Immunotherapy: Therapeutic Limitations and Next-Generation Precision Strategies.Immune network · 2026Review
- Take Five: harmonization in personalized cancer vaccines for cancer immunotherapy.Experimental & molecular medicine · 2026Review
- Combinatorial in situ cancer vaccines: unlocking broad and enhanced antitumor responses.Signal transduction and targeted therapy · 2026Review
- Tumor infiltrating lymphocytes in glioblastoma: immunobiology and translational implications.NPJ precision oncology · 2026Review
413 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
39 authors at 10 institutions in 1 country.
Patrick A OttDana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA. Electronic address: patrick_ott@dfci.harvard.edu.
Siwen Hu-LieskovanDepartment of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Bartosz ChmielowskiDepartment of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Ramaswamy GovindanWashington University School of Medicine, St. Louis, MO, USA.
Aung NaingDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nina BhardwajTisch Cancer Institute, Icahn School of Medicine, New York, NY, USA.
Kim MargolinDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Mark M AwadDana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
Matthew D HellmannMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Jessica J LinCancer Center, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA.
Terence FriedlanderDepartment of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA, USA.
Meghan E BushwayNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Kristen N BaloghNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Tracey E SciutoNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Victoria KohlerNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Samantha J TurnbullNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Rana BesadaNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Riley R CurranNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Benjamin TrappNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Julian SchererNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Asaf PoranNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Dewi HarjantoNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Dominik BarthelmeNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Ying Sonia TingNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Jesse Z DongNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Yvonne WareNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Yuting HuangNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Zhengping HuangNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Amy WanamakerNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Lisa D ClearyNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Melissa A MolesNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Kelledy MansonNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Joel GreshockNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Zakaria S KhondkerNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Ed FritschNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Michael S RooneyNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Mark DeMarioNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Richard B GaynorNeon Therapeutics/BioNTech US, Cambridge, MA, USA.
Lakshmi SrinivasanNeon Therapeutics/BioNTech US, Cambridge, MA, USA. Electronic address: lakshmi.srinivasan@biontech.us.
BioNTech (United States) · USBrigham and Women's Hospital · USUniversity of California, Los Angeles · USCity Of Hope National Medical Center · USHarvard University · USMemorial Sloan Kettering Cancer Center · USThe University of Texas MD Anderson Cancer Center · USTisch Hospital · USUniversity of California, San Francisco · USWashington University in St. Louis · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoantigens arise from mutations in cancer cells and are important targets of T cell-mediated anti-tumor immunity. Here, we report the first open-label, phase Ib clinical trial of a personalized neoantigen-based vaccine, NEO-PV-01, in combination with PD-1 blockade in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. This analysis of 82 patients demonstrated that the regimen was safe, with no treatment-related serious adverse events observed. De novo neoantigen-specific CD4
Indexed as
AgedAntigens, NeoplasmCancer VaccinesCarcinoma, Non-Small-Cell LungCD8-Positive T-LymphocytesFemaleHumansImmunotherapyKaplan-Meier EstimateMaleMelanomaMiddle AgedMutationNivolumabPrecision MedicineProgrammed Cell Death 1 ReceptorAntigens, NeoplasmCancer VaccinesNivolumabPDCD1 protein, humanProgrammed Cell Death 1 Receptoranti-PD-1cancer vaccinecheckpoint inhibitorepitope spreadimmunotherapymetastatic cancerneoantigenNEO-PV-01personalized vaccineT cell
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.